These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19882663)

  • 1. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment.
    Liang T; Wang N; Li W; Li A; Wang J; Cui J; Liu N; Li Y; Li L; Yang G; Du Z; Li D; He K; Wang G
    Proteomics; 2010 Jan; 10(1):90-8. PubMed ID: 19882663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of serum biomarkers for assessing minimal residual disease in acute leukemia by serum peptide pattern].
    Song W; Li W; Wang GJ; Wang N; Liang TT; Li Y; Cui JW
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):714-8. PubMed ID: 23978027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum proteomic profiling for the early diagnosis of colorectal cancer.
    Zhu D; Wang J; Ren L; Li Y; Xu B; Wei Y; Zhong Y; Yu X; Zhai S; Xu J; Qin X
    J Cell Biochem; 2013 Feb; 114(2):448-55. PubMed ID: 22961748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells.
    Xiang Y; Matsui T; Matsuo K; Shimada K; Tohma S; Nakamura H; Masuko K; Yudoh K; Nishioka K; Kato T
    Arthritis Rheum; 2007 Jun; 56(6):2018-30. PubMed ID: 17530642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Id4 gene methylation for detection of minimal residual disease in acute leukemia].
    Zhao Y; Yu L; Wang QS; Li HH; Bo J; Wang SH; Jin HJ; Lou FD
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):298-301. PubMed ID: 16875575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Pérez-Romano B; Ruiz-Argüelles A; Ramírez-Cisneros FJ; López-Martínez B; López-Tapia JD; Rivadeneyra-Espinoza L
    Rev Invest Clin; 2000; 52(2):118-24. PubMed ID: 10846434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The minimal residual disease (MRD) in hematological malignancies].
    Yokota S; Okamoto T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of peripheral blood progenitor cells demonstrates limitations of minimal residual disease diagnosis in a case of acute promyelocytic leukemia.
    Karlic HI; Mühlberger H; Pavlova BG; Pfeilstöcker M; Salamon J; Pittermann E; Heinz R; Koller E
    Bone Marrow Transplant; 1995 Jun; 15(6):999-1000. PubMed ID: 7581106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
    Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
    Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance and prognostic detection of minimal residual disease in acute leukemias].
    Deptała A; Widzyńska I; Kuratowska Z
    Acta Haematol Pol; 1995; 26(4):413-20. PubMed ID: 8571743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of minimal residual disease in acute leukemias by immunophenotyping of bone marrow cells].
    Deptała A; Widzyńska I; Kuratowska Z
    Acta Haematol Pol; 1995; 26(4):403-11. PubMed ID: 8571742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.
    van Stijn A; Feller N; Kok A; van der Pol MA; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Apr; 11(7):2540-6. PubMed ID: 15814631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.